Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 May;13(4):499-504.
doi: 10.1016/j.jgo.2021.11.015. Epub 2021 Dec 23.

Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains

Justin D Woods  1 , Joshua F Zeidner  2 , Hendrik W Van Deventer  2 , Katarzyna Jamieson  2 , Melissa Matson  3 , Jack Zhang  4 , William Pulley  4 , Tucker Brenizer  4 , Hyman Muss  2 , Kirsten A Nyrop  2 , Sanah N Vohra  5 , Allison M Deal  4 , Anastasia Ivanova  6 , Matthew C Foster  7
Affiliations
Clinical Trial

Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains

Justin D Woods et al. J Geriatr Oncol. 2022 May.

Abstract

Background and objectives: Novel, non-cytotoxic agents are driving a paradigm shift for treatment of older adults with acute myeloid leukemia (AML). Older patients who initially receive intensive cytotoxic induction may choose to not proceed with cytotoxic consolidation therapy. Lenalidomide is an orally-administered immunomodulatory small molecule with activity in AML and a favorable safety profile in older adults with active leukemia. We conducted a phase Ib study of lenalidomide as post-remission therapy in older adults and assessed its impact on geriatric functional domains.

Materials and methods: Participants were patients with AML over age 60 years who had undergone induction therapy and were poor candidates for cytotoxic consolidation. Lenalidomide was administered for 28 days in three dose cohorts. A Bayesian dose-escalation method determined cohort assignment and maximum tolerated dose (MTD). Geriatric assessment (GA) was performed before and after the cycle of lenalidomide.

Results: Nineteen patients with median age 68 were treated with at least one 28-day course of lenalidomide. Dose-limiting toxicities were observed in three participants at 25 mg, zero participants at 35 mg, and one participant at 50 mg. MTD was 35 mg. Median relapse-free survival was 4.3 months. GA was completed before and after treatment in fifteen patients, demonstrating improved cognitive function and no changes in physical, psychological, or social function after lenalidomide.

Conclusion: Lenalidomide can be safely administered to older adults with AML with preservation of functional domains important to older patients. Serial GA can be performed in a novel drug study as a tool to characterize treatment tolerability.

Trial registration: ClinicalTrials.gov NCT01578954.

Keywords: Acute myeloid leukemia; Geriatric assessment; Lenalidomide.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Figures

Figure 1:
Figure 1:
CONSORT diagram
Figure 2:
Figure 2:
Geriatric assessment data from Table 3. First box (blue) pre-treatment and second box (red) post-treatment.
See this image and copyright information in PMC

References

    1. National Cancer Institute SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML) (2020).
    1. Appelbaum FR, et al. Age and acute myeloid leukemia. Blood 107, 3481–3485 (2006). - PMC - PubMed
    1. Oran B & Weisdorf DJ Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97, 1916–1924 (2012). - PMC - PubMed
    1. DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383, 617–629 (2020). - PubMed
    1. Wei AH, et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. in 61st American Society of Hematology Annual Meeting LBA-3 (Blood, San Diego, CA USA, 2019).

Publication types

Associated data